Related Experiment Video

Updated: Apr 27, 2026

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

13.1K

Monocyte chemo attractant protein-1 in patients with chronic heart failure of different functional class with type 2

P Kravchun1, A Narizhna1, N Ryndina1

  • 1Kharkiv National Medical University, Ukraine.

Georgian Medical News
|July 15, 2014
PubMed

Insights

In chronic heart failure (CHF), both interleukin-1β and monocyte chemoattractant protein-1 increase with functional class. Type 2 diabetes exacerbates these profibrotic markers in CHF patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biochemistry

Background:

  • Chronic heart failure (CHF) is a complex condition often accompanied by comorbidities.
  • Type 2 diabetes is a prevalent comorbidity that can influence CHF progression and pathophysiology.
  • Interleukin-1β and monocyte chemoattractant protein-1 are key inflammatory and profibrotic mediators implicated in cardiovascular disease.

Purpose of the Study:

  • To investigate the dynamics of monocyte chemoattractant protein-1 (MCP-1) in patients with chronic heart failure (CHF).
  • To compare MCP-1 levels in CHF patients with and without type 2 diabetes across different functional classes.
  • To assess the interplay between CHF severity, type 2 diabetes, and specific cytokine/fibrosis markers.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) was used to quantify cytokine and fibrosis factor concentrations.
  • Study included 95 patients with CHF (II-III FC) due to coronary heart disease, divided into groups with and without type 2 diabetes.
  • Exclusion criteria included acute coronary syndrome and acute myocardial infarction.

Main Results:

  • Both interleukin-1β and monocyte chemoattractant protein-1 levels increased with higher New York Heart Association (NYHA) functional class in CHF patients.
  • Patients with type 2 diabetes exhibited significantly higher levels of interleukin-1β and monocyte chemoattractant protein-1 compared to those without diabetes, at the same NYHA functional class.
  • These findings suggest a negative impact of type 2 diabetes on cytokine activity and fibrosis markers in CHF.

Conclusions:

  • Monocyte chemoattractant protein-1 and interleukin-1β are elevated in CHF and correlate with disease severity.
  • Type 2 diabetes exacerbates the profibrotic and inflammatory response in chronic heart failure.
  • Targeting these pathways may offer therapeutic potential for CHF patients with diabetes.

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

747

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
861
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.7K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
621
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
1.1K